Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says

MT Newswires Live06-04 22:49

Erasca's (ERAS) early pan-RAS data have shifted the focus from whether ERAS-0015 is active to its potential commercial impact, with recent clinical results and stronger key opinion leader feedback strengthening confidence in the program's activity profile, BofA Securities said in a Thursday note.

The analyst said ERAS-0015 has shown clinically meaningful activity across non-small cell lung cancer, pancreatic, and colorectal cancers, supporting Erasca's position in the competitive RAS-targeted therapy space, with safety appearing manageable so far but longer follow-up needed to confirm durability and survival benefit.

BofA highlighted ERAS-4001 as a key pipeline opportunity in the second half of 2026 if it shows a broader therapeutic window and improved tolerability, while also citing colorectal cancer combinations and upcoming clinical readouts as near-term catalysts for sentiment and valuation.

The outlook is now more balanced after early data, with upside from further efficacy confirmation, combinations, and readouts, while risks include durability, safety, competition, and uncertainty around differentiation and market path, the report added.

BofA raised its rating on the stock to neutral from underperform and increased its price target to $16 from $9.

Shares of Erasca were up 2.9% in Thursday trading.

Price: 13.49, Change: +0.31, Percent Change: +2.35

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640165685?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640165685","market":"hk","top_or_hot":-1,"title":"Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says","media":"MT Newswires Live","content":"<html><body><p> Erasca's (ERAS) early pan-RAS data have shifted the focus from whether ERAS-0015 is active to its potential commercial impact, with recent clinical results and stronger key opinion leader feedback strengthening confidence in the program's activity profile, BofA Securities said in a Thursday note.</p><p>The analyst said ERAS-0015 has shown clinically meaningful activity across non-small cell lung cancer, pancreatic, and colorectal cancers, supporting Erasca's position in the competitive RAS-targeted therapy space, with safety appearing manageable so far but longer follow-up needed to confirm durability and survival benefit.</p><p>BofA highlighted ERAS-4001 as a key pipeline opportunity in the second half of 2026 if it shows a broader therapeutic window and improved tolerability, while also citing colorectal cancer combinations and upcoming clinical readouts as near-term catalysts for sentiment and valuation.</p><p>The outlook is now more balanced after early data, with upside from further efficacy confirmation, combinations, and readouts, while risks include durability, safety, competition, and uncertainty around differentiation and market path, the report added.</p><p>BofA raised its rating on the stock to neutral from underperform and increased its price target to $16 from $9.</p><p>Shares of Erasca were up 2.9% in Thursday trading.</p><p>Price: 13.49, Change: +0.31, Percent Change: +2.35</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nErasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-04 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Erasca's (ERAS) early pan-RAS data have shifted the focus from whether ERAS-0015 is active to its potential commercial impact, with recent clinical results and stronger key opinion leader feedback strengthening confidence in the program's activity profile, BofA Securities said in a Thursday note.</p><p>The analyst said ERAS-0015 has shown clinically meaningful activity across non-small cell lung cancer, pancreatic, and colorectal cancers, supporting Erasca's position in the competitive RAS-targeted therapy space, with safety appearing manageable so far but longer follow-up needed to confirm durability and survival benefit.</p><p>BofA highlighted ERAS-4001 as a key pipeline opportunity in the second half of 2026 if it shows a broader therapeutic window and improved tolerability, while also citing colorectal cancer combinations and upcoming clinical readouts as near-term catalysts for sentiment and valuation.</p><p>The outlook is now more balanced after early data, with upside from further efficacy confirmation, combinations, and readouts, while risks include durability, safety, competition, and uncertainty around differentiation and market path, the report added.</p><p>BofA raised its rating on the stock to neutral from underperform and increased its price target to $16 from $9.</p><p>Shares of Erasca were up 2.9% in Thursday trading.</p><p>Price: 13.49, Change: +0.31, Percent Change: +2.35</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ERAS","symbol_name":"Erasca, INC.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640165685","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640165685","pubTimestamp":1780584599,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Erasca's  early pan-RAS data have shifted the focus from whether ERAS-0015 is active to its potential commercial impact, with recent clinical results and stronger key opinion leader feedback strengthening confidence in the program's activity profile, BofA Securities said in a Thursday note.The analyst said ERAS-0015 has shown clinically meaningful activity across non-small cell lung cancer, pancreatic, and colorectal cancers, supporting Erasca's position in the competitive RAS-targeted therapy space, with safety appearing manageable so far but longer follow-up needed to confirm durability and survival benefit.BofA highlighted ERAS-4001 as a key pipeline opportunity in the second half of 2026 if it shows a broader therapeutic window and improved tolerability, while also citing colorectal cancer combinations and upcoming clinical readouts as near-term catalysts for sentiment and valuation.The outlook is now more balanced after early data, with upside from further efficacy confirmation, c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ERAS":"Erasca, INC.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"美国银行表示，随着早期RAS数据支持临床活动，Erasca认为前景更加平衡","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":1.5},"content_text":"Erasca's (ERAS) early pan-RAS data have shifted the focus from whether ERAS-0015 is active to its potential commercial impact, with recent clinical results and stronger key opinion leader feedback strengthening confidence in the program's activity profile, BofA Securities said in a Thursday note.The analyst said ERAS-0015 has shown clinically meaningful activity across non-small cell lung cancer, pancreatic, and colorectal cancers, supporting Erasca's position in the competitive RAS-targeted therapy space, with safety appearing manageable so far but longer follow-up needed to confirm durability and survival benefit.BofA highlighted ERAS-4001 as a key pipeline opportunity in the second half of 2026 if it shows a broader therapeutic window and improved tolerability, while also citing colorectal cancer combinations and upcoming clinical readouts as near-term catalysts for sentiment and valuation.The outlook is now more balanced after early data, with upside from further efficacy confirmation, combinations, and readouts, while risks include durability, safety, competition, and uncertainty around differentiation and market path, the report added.BofA raised its rating on the stock to neutral from underperform and increased its price target to $16 from $9.Shares of Erasca were up 2.9% in Thursday trading.Price: 13.49, Change: +0.31, Percent Change: +2.35","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640165685","isCrawlerRequest":true}